PX1 Research has announced the release of new batches of retatrutide and tirzepatide research peptides, manufactured in the United States under current Good Manufacturing Practice (cGMP) standards. Each batch undergoes rigorous HPLC batch verification, with Certificates of Analysis confirming purity ratings of 99% or above. This expansion of the company's dual-incretin peptide catalog provides researchers with domestically produced compounds that meet stringent quality control protocols.
The manufacturing process takes place in USA cGMP-certified facilities, which adhere to federal regulations governing facility conditions, equipment qualification, personnel training, and documentation practices. With over 16 years of peptide manufacturing expertise, PX1 Research emphasizes traceability and consistency, factors that are critical for research programs relying on reproducible experimental outcomes. For procurement teams, domestic cGMP manufacturing ensures a transparent chain of production documentation, which can significantly impact data integrity in studies where compound performance must remain consistent across replicates.
Each batch of retatrutide and tirzepatide peptides undergoes a seven-stage testing protocol prior to shipment. High-performance liquid chromatography (HPLC) serves as the core analytical method, separating peptide compounds to quantify purity with high resolution. Beyond chromatographic purity, the seven-stage framework includes tests for endotoxin contamination, amino acid sequence verification, and mass confirmation through spectrometric analysis. The result is a batch-specific Certificate of Analysis that researchers can use to validate the compound's quality before initiating experiments. Applying HPLC verification at the batch level, rather than as a periodic audit, ensures that every individual shipment is accompanied by documentation reflecting its unique test results, not just generalized lot data.
Retatrutide and tirzepatide are significant in current metabolic and endocrine research. Tirzepatide acts as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Retatrutide extends this mechanism by also engaging the glucagon receptor, making it a triple agonist. The structural complexity of these molecules demands precise manufacturing, as minor deviations can alter receptor binding profiles. PX1 Research's unified manufacturing and verification framework allows research teams to source both peptides with comparable documentation standards, which is particularly useful for studies comparing the two molecules or running parallel arms.
The newly released batches are now available through PX1 Research's catalog. The retatrutide offering can be accessed at px1research.com, and the tirzepatide offering is also available at px1research.com. Certificates of Analysis for current batch numbers are provided alongside each product listing, enabling researchers to verify purity and quality before purchase.
